|
1
|
Wang L, Huang J, Tan G, Zhang Y, Xia M,
Kang Z, Xiao Y and Lei M: Trends and hotspots in pulmonary fibrosis
biomarker research: A bibliometric analysis. Front Med (Lausanne).
12:15413642025. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Podolanczuk AJ, Thomson CC, Remy-Jardin M,
Richeldi L, Martinez FJ, Kolb M and Raghu G: Idiopathic pulmonary
fibrosis: State of the art for 2023. Eur Respir J. 61:22009572023.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jeganathan N, Corte TJ and Spagnolo P:
Editorial: Epidemiology and risk factors for interstitial lung
diseases. Front Med (Lausanne). 11:13848252024. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maher TM, Bendstrup E, Dron L, Langley J,
Smith G, Khalid JM, Patel H and Kreuter M: Global incidence and
prevalence of idiopathic pulmonary fibrosis. Respir Res.
22:1972021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zheng Q, Cox IA, Campbell JA, Xia Q,
Otahal P, de Graaff B, Corte TJ, Teoh AKY, Walters EH and Palmer
AJ: Mortality and survival in idiopathic pulmonary fibrosis: A
systematic review and meta-analysis. ERJ Open Res. 8:00591–2021.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Richeldi L, Collard HR and Jones MG:
Idiopathic pulmonary fibrosis. Lancet. 389:1941–1952. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
King TE Jr, Bradford WZ, Castro-Bernardini
S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM,
Kardatzke D, Lancaster L, et al: A phase 3 trial of pirfenidone in
patients with idiopathic pulmonary fibrosis. N Engl J Med.
370:2083–2092. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ebenezer DL, Fu P and Natarajan V:
Targeting sphingosine-1-Phosphate signaling in lung diseases.
Pharmacol Ther. 168:143–157. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mohammed S and Harikumar KB: Sphingosine
1-Phosphate: A novel target for lung disorders. Front Immunol.
8:2962017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hait NC, Allegood J, Maceyka M, Strub GM,
Harikumar KB, Singh SK, Luo C, Marmorstein R, Kordula T, Milstien S
and Spiegel S: Regulation of histone acetylation in the nucleus by
sphingosine-1-phosphate. Science. 325:1254–1257. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schwalm S, Manaila R, Oftring A, Schaefer
L, von Gunten S and Pfeilschifter J: The contribution of the
sphingosine 1-phosphate signaling pathway to chronic kidney
diseases: Recent findings and new perspectives. Pflugers Arch.
476:1845–1861. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao T, Ding T, Sun Z, Shao X, Li S, Lu H,
Yuan JH and Guo Z: SPHK1/S1P/S1PR pathway promotes the progression
of peritoneal fibrosis by mesothelial-mesenchymal transition. FASEB
J. 38:e234172024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Natarajan V, Dudek SM, Jacobson JR,
Moreno-Vinasco L, Huang LS, Abassi T, Mathew B, Zhao Y, Wang L,
Bittman R, et al: Sphingosine-1-phosphate, FTY720, and
sphingosine-1-phosphate receptors in the pathobiology of acute lung
injury. Am J Respir Cell Mol Biol. 49:6–17. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Serra M and Saba JD: Sphingosine
1-phosphate lyase, a key regulator of sphingosine 1-phosphate
signaling and function. Adv Enzyme Regul. 50:349–362. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Khan SA, Goliwas KF and Deshane JS:
Sphingosipids in lung pathology in the coronavirus disease era: A
review of sphingolipid involvement in the pathogenesis of lung
damage. Front Physiol. 12:7606382021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jozefczuk E, Guzik TJ and Siedlinski M:
Significance of sphingosine-1-phosphate in cardiovascular
physiology and pathology. Pharmacol Res. 156:1047932020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pitson SM, Xia P, Leclercq TM, Moretti PA,
Zebol JR, Lynn HE, Wattenberg BW and Vadas MA:
Phosphorylation-dependent translocation of sphingosine kinase to
the plasma membrane drives its oncogenic signalling. J Exp Med.
201:49–54. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao M, Bian R, Xu X, Zhang J, Zhang L and
Zheng Y: Sphingolipid metabolism and signalling pathways in heart
failure: From molecular mechanism to therapeutic potential. J
Inflamm Res. 18:5477–5498. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao Y, Gorshkova IA, Berdyshev E, He D,
Fu P, Ma W, Su Y, Usatyuk PV, Pendyala S, Oskouian B, et al:
Protection of LPS-induced murine acute lung injury by
sphingosine-1-phosphate lyase suppression. Am J Respir Cell Mol
Biol. 45:426–435. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Saba JD: Fifty years of lyase and a moment
of truth: Sphingosine phosphate lyase from discovery to disease. J
Lipid Res. 60:456–463. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fan X, Liu L, Shi Y, Guo F, He X, Zhao X,
Zhong D and Li G: Recent advances of the function of sphingosine
1-phosphate (S1P) receptor S1P3. J Cell Physiol. 236:1564–1578.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Maceyka M, Harikumar KB, Milstien S and
Spiegel S: Sphingosine-1-phosphate signaling and its role in
disease. Trends Cell Biol. 22:50–60. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sun G, Wang B, Wu X, Cheng J, Ye J, Wang
C, Zhu H and Liu X: How do sphingosine-1-phosphate affect immune
cells to resolve inflammation? Front Immunol. 15:13624592024.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li J, Fan Y, Tu W, Wu L, Pan Y, Zheng M,
Qu Y and Cao L: Sphingosine-1-phosphate in the regulation of
diabetes mellitus: A scientometric study to an in-depth review.
Front Endocrinol (Lausanne). 15:13776012024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kunkel GT, Maceyka M, Milstien S and
Spiegel S: Targeting the sphingosine-1-phosphate axis in cancer,
inflammation and beyond. Nat Rev Drug Discov. 12:688–702. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Glass DS, Grossfeld D, Renna HA, Agarwala
P, Spiegler P, Kasselman LJ, Glass AD, DeLeon J and Reiss AB:
Idiopathic pulmonary fibrosis: Molecular mechanisms and potential
treatment approaches. Respir Investig. 58:320–335. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu Q, Zhu D, Zou Y, Wang K, Rao P and Shen
Y: Catalpol attenuates pulmonary fibrosis by inhibiting ang II/AT1
and TGF-β/Smad-mediated epithelial mesenchymal transition. Front
Med (Lausanne). 9:8786012022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li RZ, Wang XR, Wang J, Xie C, Wang XX,
Pan HD, Meng WY, Liang TL, Li JX, Yan PY, et al: The key role of
sphingolipid metabolism in cancer: New therapeutic targets,
diagnostic and prognostic values, and anti-tumor immunotherapy
resistance. Front Oncol. 12:9416432022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Satyananda V, Oshi M, Tokumaru Y, Maiti A,
Hait N, Matsuyama R, Endo I and Takabe K: Sphingosine 1-phosphate
(S1P) produced by sphingosine kinase 1 (SphK1) and exported via
ABCC1 is related to hepatocellular carcinoma (HCC) progression. Am
J Cancer Res. 11:4394–4407. 2021.PubMed/NCBI
|
|
30
|
Zhang W, Li Y, Li F and Ling L:
Sphingosine-1-phosphate receptor modulators in stroke treatment. J
Neurochem. 162:390–403. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Theilmeier G, Schmidt C, Herrmann J, Keul
P, Schäfers M, Herrgott I, Mersmann J, Larmann J, Hermann S,
Stypmann J, et al: High-density lipoproteins and their constituent,
sphingosine-1-phosphate, directly protect the heart against
ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid
receptor. Circulation. 114:1403–1409. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ziegler AC and Gräler MH: Barrier
maintenance by S1P during inflammation and sepsis. Tissue Barriers.
9:19400692021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang F and Lu Y: The Sphingosine
1-Phosphate axis: An emerging therapeutic opportunity for
endometriosis. Reprod Sci. 30:2040–2059. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pyne NJ, Dubois G and Pyne S: Role of
sphingosine 1-phosphate and lysophosphatidic acid in fibrosis.
Biochim Biophys Acta. 1831:228–238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Donati C, Cencetti F, Bernacchioni C,
Vannuzzi V and Bruni P: Role of sphingosine 1-phosphate signalling
in tissue fibrosis. Cell Signal. 78:1098612021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang L, Yue S, Yang L, Liu X, Han Z, Zhang
Y and Li L: Sphingosine kinase/sphingosine 1-phosphate (S1P)/S1P
receptor axis is involved in liver fibrosis-associated
angiogenesis. J Hepatol. 59:114–123. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Milara J, Navarro R, Juan G, Peiró T,
Serrano A, Ramón M, Morcillo E and Cortijo J:
Sphingosine-1-phosphate is increased in patients with idiopathic
pulmonary fibrosis and mediates epithelial to mesenchymal
transition. Thorax. 67:147–156. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huang LS, Berdyshev E, Mathew B, Fu P,
Gorshkova IA, He D, Ma W, Noth I, Ma SF, Pendyala S, et al:
Targeting sphingosine kinase 1 attenuates bleomycin-induced
pulmonary fibrosis. FASEB J. 27:1749–1760. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Medzhitov R: Inflammation 2010: new
adventures of an old flame. Cell. 140:771–776. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng
J, Li Y, Wang X and Zhao L: Inflammatory responses and
inflammation-associated diseases in organs. Oncotarget.
9:7204–7218. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kaminska B: MAPK signalling pathways as
molecular targets for Anti-inflammatory therapy-from molecular
mechanisms to therapeutic benefits. Biochim Biophys Acta.
1754:253–262. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu T, Zhang L, Joo D and Sun SC: NF-κB
signaling in inflammation. Signal Transduct Target Ther.
2:170232017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jayant G, Kuperberg S, Somnay K and
Wadgaonkar R: The role of sphingolipids in regulating vascular
permeability in idiopathic pulmonary fibrosis. Biomedicines.
11:17282023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Moss BJ, Ryter SW and Rosas IO: Pathogenic
mechanisms underlying idiopathic pulmonary fibrosis. Annu Rev
Pathol. 17:515–546. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Jo H, Shim K and Jeoung D: The crosstalk
between FcεRI and sphingosine signaling in allergic inflammation.
Int J Mol Sci. 23:138922022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yang J, Tang X, Li B and Shi J:
Sphingosine 1-phosphate receptor 2 mediated early stages of
pancreatic and systemic inflammatory responses via NF-kappa B
activation in acute pancreatitis. Cell Commun Signal. 20:1572022.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zheng Z, Zeng YZ, Ren K, Zhu X, Tan Y, Li
Y, Li Q and Yi GH: S1P promotes inflammation-induced tube formation
by HLECs via the S1PR1/NF-κB pathway. Int Immunopharmacol.
66:224–235. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Xiong W, Chen S, Xiang H, Zhao S, Xiao J,
Li J, Liu Y, Shu Z, Ouyang J, Zhang J, et al: S1PR1 attenuates
pulmonary fibrosis by inhibiting EndMT and improving endothelial
barrier function. Pulm Pharmacol Ther. 81:1022282023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hao M, Fu R, Tai J, Tian Z, Yuan X, Chen
Y, Wang M, Jiang H, Ji M, Lai F, et al: S1PR1 serves as a viable
drug target against pulmonary fibrosis by increasing the integrity
of the endothelial barrier of the lung. Acta Pharm Sin B.
13:1110–1127. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Di Paolo A, Vignini A, Alia S, Membrino V,
Delli Carpini G, Giannella L and Ciavattini A: Pathogenic role of
the Sphingosine 1-Phosphate (S1P) pathway in common gynecologic
disorders (GDs): A possible novel therapeutic target. Int J Mol
Sci. 23:135382022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Qiu H, Liu J, You J, Zhou O, Hao C, Shu Y,
Ma D, Zou W, Zhang L, Liu E, et al: Inhibition of sphingosine
1-phosphate receptor 3 ameliorates bleomycin-induced pulmonary
fibrosis by suppressing macrophage M2 polarization. Genes Dis.
12:1012442024. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Sobel K, Menyhart K, Killer N, Renault B,
Bauer Y, Studer R, Steiner B, Bolli MH, Nayler O and Gatfield J:
Sphingosine 1-phosphate (S1P) receptor agonists mediate
pro-fibrotic responses in normal human lung fibroblasts via S1P2
and S1P3 receptors and Smad-independent signaling. J Biol Chem.
288:14839–14851. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Knipe RS, Spinney JJ, Abe EA, Probst CK,
Franklin A, Logue A, Giacona F, Drummond M, Griffith J, Brazee PL,
et al: Endothelial-specific loss of Sphingosine-1-Phosphate
receptor 1 increases vascular permeability and exacerbates
Bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol.
66:38–52. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sammani S, Moreno-Vinasco L, Mirzapoiazova
T, Singleton PA, Chiang ET, Evenoski CL, Wang T, Mathew B, Husain
A, Moitra J, et al: Differential effects of sphingosine 1-phosphate
receptors on airway and vascular barrier function in the murine
lung. Am J Respir Cell Mol Biol. 43:394–402. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Shea BS, Brooks SF, Fontaine BA, Chun J,
Luster AD and Tager AM: Prolonged exposure to sphingosine
1-phosphate receptor-1 agonists exacerbates vascular leak,
fibrosis, and mortality after lung injury. Am J Respir Cell Mol
Biol. 43:662–673. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Chen Y, Zhang Y, Rao C, Huang J and Qing
Q: Deletion of sphingosine kinase 2 attenuates cigarette
smoke-mediated chronic obstructive pulmonary disease-like symptoms
by reducing lung inflammation. Biomol Biomed. 23:259–270. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hou L, Yang L, Chang N, Zhao X, Zhou X,
Dong C, Liu F, Yang L and Li L: Macrophage sphingosine 1-Phosphate
Receptor 2 blockade attenuates liver inflammation and fibrogenesis
triggered by NLRP3 inflammasome. Front Immunol. 11:11492020.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Xia C, Cheng L, Zhao W, Chang A, Wang Z,
Liu H, Pan X, Li W, Koji S, Li Z, et al: LncRNA SYISL promotes
fibroblast myofibroblast transition via miR-23a-mediated TRIOBP
regulation. Cell Mol Life Sci. 82:2142025. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Panagiotidis GD, Vasquez-Pacheco E, Chu X,
Seeger W, El Agha E, Bellusci S and Lingampally A: Revisiting
pulmonary fibrosis: Inflammatory dynamics of the
lipofibroblast-to-inflammatory lipofibroblast-to-activated
myofibroblast reversible switch. Front Immunol. 16:16095092025.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Mo C, Xie S, Liu B, Zhong W, Zeng T, Huang
S, Lai Y, Deng G, Zhou C, Yan W, et al: Indoleamine 2,3-dioxygenase
1 limits hepatic inflammatory cells recruitment and promotes bile
duct ligation-induced liver fibrosis. Cell Death Dis. 12:162021.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ju X, Wang K, Wang C, Zeng C, Wang Y and
Yu J: Regulation of myofibroblast dedifferentiation in pulmonary
fibrosis. Respir Res. 25:2842024. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zhao T and Su Y: Mechanisms and
therapeutic potential of myofibroblast transformation in pulmonary
fibrosis. J Respir Biol Transl Med. 2:100012025.PubMed/NCBI
|
|
63
|
Kawashima T, Yamazaki R, Matsuzawa Y,
Yamaura E, Takabatake M, Otake S, Ikawa Y, Nakamura H, Fujino H and
Murayama T: Contrary effects of sphingosine-1-phosphate on
expression of α-smooth muscle actin in transforming growth factor
β1-stimulated lung fibroblasts. Eur J Pharmacol. 696:120–129. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Urata Y, Nishimura Y, Hirase T and
Yokoyama M: Sphingosine 1-phosphate induces alpha-smooth muscle
actin expression in lung fibroblasts via Rho-kinase. Kobe J Med
Sci. 51:17–27. 2005.PubMed/NCBI
|
|
65
|
Takuwa Y, Ikeda H, Okamoto Y, Takuwa N and
Yoshioka K: Sphingosine-1-phosphate as a mediator involved in
development of fibrotic diseases. Biochim Biophys Acta.
1831:185–192. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kono Y, Nishiuma T, Nishimura Y, Kotani Y,
Okada T, Nakamura S and Yokoyama M: Sphingosine kinase 1 regulates
differentiation of human and mouse lung fibroblasts mediated by
TGF-beta1. Am J Respir Cell Mol Biol. 37:395–404. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Keller CD, Rivera Gil P, Tölle M, van der
Giet M, Chun J, Radeke HH, Schäfer-Korting M and Kleuser B:
Immunomodulator FTY720 induces myofibroblast differentiation via
the lysophospholipid receptor S1P3 and Smad3 signaling. Am J
Pathol. 170:281–292. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Sobel K, Monnier L, Menyhart K, Bolinger
M, Studer R, Nayler O and Gatfield J: FTY720 phosphate activates
Sphingosine-1-Phosphate receptor 2 and selectively couples to
Gα12/13/Rho/ROCK to induce myofibroblast contraction. Mol
Pharmacol. 87:916–927. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Hill C, Li J, Liu D, Conforti F, Brereton
CJ, Yao L, Zhou Y, Alzetani A, Chee SJ, Marshall BG, et al:
Autophagy inhibition-mediated epithelial-mesenchymal transition
augments local myofibroblast differentiation in pulmonary fibrosis.
Cell Death Dis. 10:5912019. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Wei J, Zhao Q, Yang G, Huang R, Li C, Qi
Y, Hao C and Yao W: Mesenchymal stem cells ameliorate
silica-induced pulmonary fibrosis by inhibition of inflammation and
epithelial-mesenchymal transition. J Cell Mol Med. 25:6417–6428.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Kim KK, Kugler MC, Wolters PJ, Robillard
L, Galvez MG, Brumwell AN, Sheppard D and Chapman HA: Alveolar
epithelial cell mesenchymal transition develops in vivo during
pulmonary fibrosis and is regulated by the extracellular matrix.
Proc Natl Acad Sci USA. 103:13180–13185. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Riemma MA, Cerqua I, Romano B, Irollo E,
Bertolino A, Camerlingo R, Granato E, Rea G, Scala S, Terlizzi M,
et al: Sphingosine-1-phosphate/TGF-β axis drives epithelial
mesenchymal transition in asthma-like disease. Br J Pharmacol.
179:1753–1768. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Huang LS, Berdyshev EV, Tran JT, Xie L,
Chen J, Ebenezer DL, Mathew B, Gorshkova I, Zhang W, Reddy SP, et
al: Sphingosine-1-phosphate lyase is an endogenous suppressor of
pulmonary fibrosis: Role of S1P signalling and autophagy. Thorax.
70:1138–1148. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Mu SY, Xu R, Wu XF, Cheng YY, Sun ZM, Liu
HT, Shao HB, Zhang XN, Zhang XN, Yang M, et al: Inhibition of
sphingosine-1-phosphate receptor-2 attenuates idiopathic pulmonary
fibrosis by preventing its binding to dapper1 in bronchial
epithelial cells. Br J Pharmacol. 183:957–972. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Lu G, Wang Y, Shi Y, Zhang Z, Huang C, He
W, Wang C and Shen HM: Autophagy in health and disease: From
molecular mechanisms to therapeutic target. MedComm (2020).
3:e1502022. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Xiao S, Peng K, Li C, Long Y and Yu Q: The
role of sphingosine-1-phosphate in autophagy and related disorders.
Cell Death Discov. 9:3802023. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Sosulski ML, Gongora R, Danchuk S, Dong C,
Luo F and Sanchez CG: Deregulation of selective autophagy during
aging and pulmonary fibrosis: The role of TGFβ1. Aging Cell.
14:774–783. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Patel AS, Lin L, Geyer A, Haspel JA, An
CH, Cao J, Rosas IO and Morse D: Autophagy in idiopathic pulmonary
fibrosis. PLoS One. 7:e413942012. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Lv X, Li K and Hu Z: Autophagy and
pulmonary fibrosis. Adv Exp Med Biol. 1207:569–579. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Hill C and Wang Y: Autophagy in pulmonary
fibrosis: Friend or foe? Genes Dis. 9:1594–1607. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Tatler AL and Jenkins G:
Sphingosine-1-phosphate metabolism: Can its enigmatic lyase promote
the autophagy of fibrosis? Thorax. 70:1106–1107. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Huang LS and Natarajan V: Sphingolipids in
pulmonary fibrosis. Adv Biol Regul. 57:55–63. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Goel K, Beatman EL, Egersdorf N, Scruggs
A, Cao D, Berdyshev EV, Schweitzer KS and Petrache I: Sphingosine 1
phosphate (S1P) Receptor 1 is decreased in human lung microvascular
endothelial cells of smokers and mediates S1P effect on autophagy.
Cells. 10:12002021. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Liu H, Li L, Chen Z, Song Y, Liu W, Gao G,
Li L, Jiang J, Xu C, Yan G and Cui H: S1PR2 inhibition attenuates
allergic asthma possibly by regulating autophagy. Front Pharmacol.
11:5980072021. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Weigel C, Hüttner SS, Ludwig K, Krieg N,
Hofmann S, Schröder NH, Robbe L, Kluge S, Nierhaus A, Winkler MS,
et al: S1P lyase inhibition protects against sepsis by promoting
disease tolerance via the S1P/S1PR3 axis. EBioMedicine.
58:1028982020. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Jelic MD, Mandic AD, Maricic SM and
Srdjenovic BU: Oxidative stress and its role in cancer. J Cancer
Res Ther. 17:22–28. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Veith C, Boots AW, Idris M, van Schooten
FJ and van der Vliet A: Redox imbalance in idiopathic pulmonary
fibrosis: A role for oxidant Cross-talk between NADPH oxidase
enzymes and mitochondria. Antioxid Redox Signal. 31:1092–1115.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Toussaint O, Medrano EE and von Zglinicki
T: Cellular and molecular mechanisms of stress-induced premature
senescence (SIPS) of human diploid fibroblasts and melanocytes. Exp
Gerontol. 35:927–945. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Raish M, Ahmad A, Ahmad Ansari M, Ahad A,
Al-Jenoobi FI, Al-Mohizea AM, Khan A and Ali N: Sinapic acid
ameliorates bleomycin-induced lung fibrosis in rats. Biomed
Pharmacother. 108:224–231. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Psathakis K, Mermigkis D, Papatheodorou G,
Loukides S, Panagou P, Polychronopoulos V, Siafakas NM and Bouros
D: Exhaled markers of oxidative stress in idiopathic pulmonary
fibrosis. Eur J Clin Invest. 36:362–367. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Bargagli E, Penza F, Vagaggini C, Magi B,
Perari MG and Rottoli P: Analysis of carbonylated proteins in
bronchoalveolar lavage of patients with diffuse lung diseases.
Lung. 185:139–144. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Lan T, Liu W, Xie X, Xu S, Huang K, Peng
J, Shen X, Liu P, Wang L, Xia P and Huang H: Sphingosine kinase-1
pathway mediates high glucose-induced fibronectin expression in
glomerular mesangial cells. Mol Endocrinol. 25:2094–2105. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Maceyka M, Milstien S and Spiegel S:
Shooting the messenger: Oxidative stress regulates
sphingosine-1-phosphate. Circ Res. 100:7–9. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Martín-Montañez E, Pavia J, Valverde N,
Boraldi F, Lara E, Oliver B, Hurtado-Guerrero I, Fernandez O and
Garcia-Fernandez M: The S1P mimetic fingolimod phosphate regulates
mitochondrial oxidative stress in neuronal cells. Free Radic Biol
Med. 137:116–130. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Harijith A, Pendyala S, Ebenezer DL, Ha
AW, Fu P, Wang YT, Ma K, Toth PT, Berdyshev EV, Kanteti P and
Natarajan V: Hyperoxia-induced p47phox activation and ROS
generation is mediated through S1P transporter Spns2, and
S1P/S1P1&2 signaling axis in lung endothelium. Am J Physiol
Lung Cell Mol Physiol. 311:L337–L351. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Zhou J, Song Y, Wang X, Li X, Liu C, Tian
C, Wang C, Li L, Yan G and Cui H: JTE-013 alleviates pulmonary
fibrosis by affecting the RhoA/YAP pathway and mitochondrial
Fusion/fission. Pharmaceuticals (Basel). 16:14442023. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Harijith A, Pendyala S, Reddy NM, Bai T,
Usatyuk PV, Berdyshev E, Gorshkova I, Huang LS, Mohan V, Garzon S,
et al: Sphingosine kinase 1 deficiency confers protection against
hyperoxia-induced bronchopulmonary dysplasia in a murine model:
Role of S1P signaling and Nox proteins. Am J Pathol. 183:1169–1182.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Huang LS, Sudhadevi T, Fu P, Punathikannan
PK, Ebenezer DL, Ramchandran R, Putherickal V, Cheresh P, Zhou G,
Ha AW, et al: Sphingosine Kinase 1/S1P signaling contributes to
pulmonary fibrosis by activating Hippo/YAP pathway and
mitochondrial reactive oxygen species in lung fibroblasts. Int J
Mol Sci. 21:20642020. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Zhang X, Cai Y, Zhang W and Chen X:
Quercetin ameliorates pulmonary fibrosis by inhibiting SphK1/S1P
signaling. Biochem Cell Biol. 96:742–751. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Gorshkova I, Zhou T, Mathew B, Jacobson
JR, Takekoshi D, Bhattacharya P, Smith B, Aydogan B, Weichselbaum
RR, Natarajan V, et al: Inhibition of serine palmitoyltransferase
delays the onset of radiation-induced pulmonary fibrosis through
the negative regulation of sphingosine kinase-1 expression. J Lipid
Res. 53:1553–1568. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Zeyada MS, Eraky SM and El-Shishtawy MM:
Trigonelline mitigates bleomycin-induced pulmonary inflammation and
fibrosis: Insight into NLRP3 inflammasome and SPHK1/S1P/Hippo
signaling modulation. Life Sci. 336:1222722024. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Lu F, Wang G, Yang X, Luo J, Ma H, Pan L,
Yao Y and Xie K: SPHK1-S1p Signaling Drives Fibrocyte-mediated
pulmonary fibrosis: Mechanistic insights and therapeutic potential.
Pharmaceuticals (Basel). 18:8592025. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Mammoliti O, Palisse A, Joannesse C, El
Bkassiny S, Allart B, Jaunet A, Menet C, Coornaert B, Sonck K, Duys
I, et al: Discovery of the S1P2 Antagonist GLPG2938
(1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea),
a preclinical candidate for the treatment of idiopathic pulmonary
fibrosis. J Med Chem. 64:6037–6058. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Allameh A, Atashbasteh M, Mortaz E, Naeeni
B and Jafari-Khorchani M: Down-regulation of key regulatory factors
in sphingosine-1-phosphate (S1P) pathway in human lung fibroblasts
transfected with selected microRNAs. Mol Biol Res Commun.
13:201–209. 2024.PubMed/NCBI
|
|
105
|
Arora S, Singh P, Tabassum G, Dohare R and
Syed MA: miR-495-3p regulates sphingolipid metabolic reprogramming
to induce Sphk1/ceramide mediated mitophagy and apoptosis in NSCLC.
Free Radic Biol Med. 189:71–84. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Bonauer A, Carmona G, Iwasaki M, Mione M,
Koyanagi M, Fischer A, Burchfield J, Fox H, Doebele C, Ohtani K, et
al: MicroRNA-92a controls angiogenesis and functional recovery of
ischemic tissues in mice. Science. 324:1710–1713. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Pi J, Tao T, Zhuang T, Sun H, Chen X, Liu
J, Cheng Y, Yu Z, Zhu HH, Gao WQ, et al: A
MicroRNA302-367-Erk1/2-Klf2-S1pr1 pathway prevents tumor growth via
restricting angiogenesis and improving vascular stability. Circ
Res. 120:85–98. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Zhou P, Huang G, Zhao Y, Zhong D, Xu Z,
Zeng Y, Zhang Y, Li S and He F: MicroRNA-363-mediated
downregulation of S1PR1 suppresses the proliferation of
hepatocellular carcinoma cells. Cell Signal. 26:1347–1354. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Zhang SL and Liu L: MicroRNA-148a inhibits
hepatocellular carcinoma cell invasion by targeting
sphingosine-1-phosphate receptor 1. Exp Ther Med. 9:579–584. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Brinkmann V: FTY720 (fingolimod) in
Multiple Sclerosis: Therapeutic effects in the immune and the
central nervous system. Br J Pharmacol. 158:1173–1182. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Diouf I, Malpas CB, Sharmin S, Roos I,
Horakova D, Kubala Havrdova E, Patti F, Shaygannejad V, Ozakbas S,
Eichau S, et al: Effectiveness of multiple disease-modifying
therapies in relapsing-remitting multiple sclerosis: Causal
inference to emulate a multiarm randomised trial. J Neurol
Neurosurg Psychiatry. 94:1004–1011. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Irmak Ön B, Havla J and Mansmann U:
Multivariable prognostic prediction of efficacy and safety outcomes
and response to fingolimod in people with relapsing-remitting
multiple sclerosis. Mult Scler Relat Disord. 93:1062472025.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Ahmed N, Linardi D, Muhammad N, Chiamulera
C, Fumagalli G, Biagio LS, Gebrie MA, Aslam M, Luciani GB, Faggian
G, et al: Sphingosine 1-phosphate receptor modulator fingolimod
(FTY720) attenuates myocardial fibrosis in Post-heterotopic heart
transplantation. Front Pharmacol. 8:6452017. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Tian T, Zhang J, Zhu X, Wen S, Shi D and
Zhou H: FTY720 ameliorates renal fibrosis by simultaneously
affecting leucocyte recruitment and TGF-β signalling in
fibroblasts. Clin Exp Immunol. 190:68–78. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Baweja S, Kumari A, Negi P, Tomar A,
Tripathi DM, Mourya AK, Rastogi A, Subudhi PD, Thangariyal S, Kumar
G, et al: Hepatopulmonary syndrome is associated with low
sphingosine-1-phosphate levels and can be ameliorated by the
functional agonist fingolimod. J Hepatol. 79:167–180. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Jin Y, Liu W, Gao G, Song Y, Liu H, Li L,
Zhou J, Yan G and Cui H: Effect of FTY-720 on pulmonary fibrosis in
mice via the TGF-β1 signaling pathway and autophagy. Biomol Ther
(Seoul). 31:434–445. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Müller HC, Hocke AC, Hellwig K, Gutbier B,
Peters H, Schönrock SM, Tschernig T, Schmiedl A, Hippenstiel S,
N'Guessan PD, et al: The Sphingosine-1 Phosphate receptor agonist
FTY720 dose dependently affected endothelial integrity in vitro and
aggravated ventilator-induced lung injury in mice. Pulm Pharmacol
Ther. 24:377–385. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Oo ML, Chang SH, Thangada S, Wu MT, Rezaul
K, Blaho V, Hwang SI, Han DK and Hla T: Engagement of
S1P1-degradative mechanisms leads to vascular leak in mice. J Clin
Invest. 121:2290–2300. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Bittner S and Wiendl H:
Neuroimmunotherapies Targeting T cells: From pathophysiology to
therapeutic applications. Neurotherapeutics. 13:4–19. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Chun J and Hartung HP: Mechanism of action
of oral fingolimod (FTY720) in multiple sclerosis. Clin
Neuropharmacol. 33:91–101. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Üzer F, Akanlar S and Çilli A: Real-life
data in the treatment and follow-up of idiopathic pulmonary
fibrosis: A single-center study. Tuberk Toraks. 71:347–355. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Guenther A, Tello S, Schoppe MC,
Pons-Kuehnemann J, Seeger W, Stiben J, Tello K, Molina Molina M,
Vancheri C, Crestani B and Krauss E: Pulmonary Hypertension drives
prognosis in idiopathic pulmonary fibrosis: Insights from the
European IPF registry. J Clin Med. 14:73522025. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Bellanca CM, Augello E, Mariottini A,
Bonaventura G, La Cognata V, Di Benedetto G, Cantone AF, Attaguile
G, Di Mauro R, Cantarella G, et al: Disease modifying strategies in
multiple sclerosis: New rays of hope to combat disability? Curr
Neuropharmacol. 22:1286–1326. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Roy R, Alotaibi AA and Freedman MS:
Sphingosine 1-Phosphate receptor modulators for multiple sclerosis.
CNS Drugs. 35:385–402. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Li J, Huang Y, Zhang Y, Liu P, Liu M,
Zhang M and Wu R: S1P/S1PR signaling pathway advancements in
autoimmune diseases. Biomol Biomed. 23:922–935. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Bravo GÁ, Cedeño RR, Casadevall MP and
Ramió-Torrentà L: Sphingosine-1-Phosphate (S1P) and S1P signaling
pathway modulators, from current insights to future perspectives.
Cells. 11:20582022. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Sands BE, D'Haens G, Panaccione R,
Regueiro M, Ghosh S, Hudesman D, Ahmad HA, Mehra D, Wu H, Jain A,
et al: Ozanimod in patients with moderate to severe ulcerative
colitis naive to advanced therapies. Clin Gastroenterol Hepatol.
22:2084–2095.e4. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Harris S, Feagan BG, Hanauer S, Vermeire
S, Ghosh S, Yan J, Wu C, Hu Y, Maddux R, Wolf DC and D'Haens G:
Ozanimod differentially impacts circulating lymphocyte subsets in
patients with moderately to severely active Crohn's disease. Dig
Dis Sci. 69:2044–2054. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Pérez-Jeldres T, Alvarez-Lobos M and
Rivera-Nieves J: Targeting Sphingosine-1-Phosphate signaling in
Immune-mediated diseases: Beyond multiple sclerosis. Drugs.
81:985–1002. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Lellouche F, Blais-Lecours P, Maltais F,
Sarrazin JF, Rola P, Nguyen T, Châteauvert N and Marsolais D:
Ozanimod therapy in patients with COVID-19 requiring oxygen
support: A randomized Open-label pilot trial. Chest. 165:810–819.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Paik J: Ozanimod: A review in ulcerative
colitis. Drugs. 82:1303–1313. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Cocconcelli E, Tonelli R, Abbati G,
Marchioni A, Castaniere I, Pelizzaro F, Russo FP, Vegetti A,
Balestro E, Pietrangelo A, et al: Subclinical liver fibrosis in
patients with idiopathic pulmonary fibrosis. Intern Emerg Med.
16:349–357. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Sands BE, Schreiber S, Blumenstein I,
Chiorean MV, Ungaro RC and Rubin DT: Clinician's Guide to using
ozanimod for the treatment of ulcerative colitis. J Crohns Colitis.
17:2012–2025. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Coyle PK, Freedman MS, Cohen BA, Cree BAC
and Markowitz CE: Sphingosine 1-phosphate receptor modulators in
multiple sclerosis treatment: A practical review. Ann Clin Transl
Neurol. 11:842–855. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
McGinley MP and Cohen JA: Sphingosine
1-phosphate receptor modulators in multiple sclerosis and other
conditions. Lancet. 398:1184–1194. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Tanaka S, Zheng S, Kharel Y, Fritzemeier
RG, Huang T, Foster D, Poudel N, Goggins E, Yamaoka Y, Rudnicka KP,
et al: Sphingosine 1-phosphate signaling in perivascular cells
enhances inflammation and fibrosis in the kidney. Sci Transl Med.
14:eabj26812022. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Hisano Y, Kobayashi N, Yamaguchi A and
Nishi T: Mouse SPNS2 functions as a sphingosine-1-phosphate
transporter in vascular endothelial cells. PLoS One. 7:e389412012.
View Article : Google Scholar : PubMed/NCBI
|
